Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 14.748
Filtrer
1.
Aust J Gen Pract ; 53(7): 499-503, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38959520

RÉSUMÉ

BACKGROUND AND OBJECTIVES: There were 82.4 million new gonorrhoea cases worldwide in 2020. Dual treatment with ceftriaxone or cefixime and azithromycin or doxycycline is currently recommended for gonorrhoea in Indonesia. However, reduced susceptibility and resistance to cephalosporins and azithromycin are increasing. We evaluated the susceptibility pattern of Neisseria gonorrhoeae to cefixime, ceftriaxone, azithromycin and doxycycline. METHOD: N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria. RESULTS: Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates. DISCUSSION: A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.


Sujet(s)
Antibactériens , Azithromycine , Ceftriaxone , Doxycycline , Gonorrhée , Tests de sensibilité microbienne , Neisseria gonorrhoeae , Humains , Indonésie , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , Gonorrhée/traitement médicamenteux , Mâle , Tests de sensibilité microbienne/méthodes , Azithromycine/usage thérapeutique , Doxycycline/usage thérapeutique , Ceftriaxone/usage thérapeutique , Ceftriaxone/pharmacologie , Adulte , Céfixime/usage thérapeutique , Céfixime/pharmacologie , Soins de santé primaires/statistiques et données numériques , Résistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Association de médicaments/méthodes
2.
PLoS One ; 19(7): e0305296, 2024.
Article de Anglais | MEDLINE | ID: mdl-38968209

RÉSUMÉ

BACKGROUND: Quality assessments of gonococcal surveillance data are critical to improve data validity and to enhance the value of surveillance findings. Detecting data errors by systematic audits identifies areas for quality improvement. We designed and implemented an internal audit process to evaluate the accuracy and completeness of surveillance data for the Thailand Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP). METHODS: We conducted a data quality audit of source records by comparison with the data stored in the EGASP database for five audit cycles from 2015-2021. Ten percent of culture-confirmed cases of Neisseria gonorrhoeae were randomly sampled along with any cases identified with elevated antimicrobial susceptibility testing results and cases with repeat infections. Incorrect and incomplete data were investigated, and corrective action and preventive actions (CAPA) were implemented. Accuracy was defined as the percentage of identical data in both the source records and the database. Completeness was defined as the percentage of non-missing data from either the source document or the database. Statistical analyses were performed using the t-test and the Fisher's exact test. RESULTS: We sampled and reviewed 70, 162, 85, 68, and 46 EGASP records during the five audit cycles. Overall accuracy and completeness in the five audit cycles ranged from 93.6% to 99.4% and 95.0% to 99.9%, respectively. Overall, completeness was significantly higher than accuracy (p = 0.017). For each laboratory and clinical data element, concordance was >85% in all audit cycles except for two laboratory data elements in two audit cycles. These elements significantly improved following identification and CAPA implementation. DISCUSSION: We found a high level of data accuracy and completeness in the five audit cycles. The implementation of the audit process identified areas for improvement. Systematic quality assessments of laboratory and clinical data ensure high quality EGASP surveillance data to monitor for antimicrobial resistant Neisseria gonorrhoeae in Thailand.


Sujet(s)
Exactitude des données , Gonorrhée , Neisseria gonorrhoeae , Thaïlande/épidémiologie , Humains , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Neisseria gonorrhoeae/isolement et purification , Gonorrhée/épidémiologie , Gonorrhée/microbiologie , Gonorrhée/traitement médicamenteux , Gonorrhée/diagnostic , Antibactériens/pharmacologie , Tests de sensibilité microbienne/normes , Bases de données factuelles , Surveillance de la population/méthodes , Résistance bactérienne aux médicaments
3.
Sex Health ; 212024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39008622

RÉSUMÉ

Background Gonorrhoea notifications have increased substantially in Australia over the past decade. Neisseria gonorrhoeae is already highly resistant to several antibiotics and so, alternatives to first-line treatment are generally strongly discouraged. The penicillin allergy label (AL) on patient medical records has previously been shown to influence prescribing practices, to the detriment of best-practice management and antimicrobial stewardship. This study aimed to understand how the penicillin AL influences antibiotic selection for gonorrhoea treatment at Canberra Sexual Health Centre. Methods A retrospective chart audit of gonorrhoea cases treated at Canberra Sexual Health Centre between January 2020 and October 2023 (n =619 patients, n =728 cases). Antibiotic selection was assessed according to penicillin AL status. Ceftriaxone selection was assessed according to penicillin allergy severity reported in the medical records and as determined using a validated antibiotic allergy assessment tool. Results Cases with a penicillin AL were more likely to receive antibiotics other than ceftriaxone (n =7/41, 17.1%) than cases without the label (n =8/687, 1.2%, P n =28/41, 68.3%) to apply the assessment tool. Those reported as low-severity in the records were more likely to receive ceftriaxone (n =21/22, 95.5%) than those reported as moderate-high (n =7/11, 63.6%) or unreported (n =6/8, 0.75%). Conclusions Treatment of gonorrhoea in outpatient settings requires an understanding of penicillin allergy, and the ability to quickly and accurately identify penicillin-AL patients who can safely tolerate ceftriaxone. Institutionally endorsed penicillin allergy de-labelling protocols and access to easy-to-navigate prescribing advice within national sexually transmitted infection management guidelines would support this.


Sujet(s)
Antibactériens , Ceftriaxone , Hypersensibilité médicamenteuse , Gonorrhée , Pénicillines , Humains , Gonorrhée/traitement médicamenteux , Ceftriaxone/usage thérapeutique , Études rétrospectives , Antibactériens/usage thérapeutique , Pénicillines/usage thérapeutique , Pénicillines/effets indésirables , Femelle , Mâle , Adulte , Neisseria gonorrhoeae , Australie , Dossiers médicaux , Types de pratiques des médecins/statistiques et données numériques , Adulte d'âge moyen , Étiquetage de médicament
4.
MSMR ; 31(6): 34-42, 2024 Jun 20.
Article de Anglais | MEDLINE | ID: mdl-38981080

RÉSUMÉ

This report summarizes incidence rates and trends of sexually transmitted infections (STIs) from 2015 through 2023 among active component service members of the U.S. Armed Forces. The data compiled for this report are derived from the medical surveillance of chlamydia, gonorrhea, and syphilis as nationally notifiable diseases. Case data for 2 additional STIs, human papilloma virus (HPV) and genital herpes simplex virus (HSV), are also presented. The crude total case rates of chlamydia and gonorrhea initially rose by an average of 6.7% and 9.8% per year, respectively, until 2019. From 2020 onwards, rates steadily declined. By 2023, chlamydia rates had dropped by approximately 39%, while gonorrhea rates had fallen by more than 40% for female, and 19% for male, service members. Initially syphilis increased, on average, 10% annually from 2015 to 2019, then declined in 2020, but resumed its upward trend through 2023, nearly doubling the 2015 rate in 2023. The total crude annual incidence rates of genital HPV and HSV exhibited downward trends in general over the surveillance period, decreasing by 30.7% and 24.7%, respectively. Age- and gender-adjusted case rates for chlamydia, gonorrhea, and syphilis remain elevated within the U.S. Armed Forces compared to the general U.S. population, which may be due to factors that include mandatory STI screening, more complete reporting, incomplete adjustment for age distribution, and inequitable comparisons between the military active duty and general U.S. populations. Social restrictions enacted during the COVID-19 pandemic may have contributed to declines in true case rates and screening coverage.


Sujet(s)
Infections à Chlamydia , Gonorrhée , Herpès génital , Personnel militaire , Surveillance de la population , Maladies sexuellement transmissibles , Syphilis , Humains , États-Unis/épidémiologie , Personnel militaire/statistiques et données numériques , Femelle , Mâle , Adulte , Incidence , Gonorrhée/épidémiologie , Maladies sexuellement transmissibles/épidémiologie , Syphilis/épidémiologie , Infections à Chlamydia/épidémiologie , Jeune adulte , Herpès génital/épidémiologie , Infections à papillomavirus/épidémiologie , COVID-19/épidémiologie , Adulte d'âge moyen
5.
Cell Rep Med ; 5(7): 101643, 2024 Jul 16.
Article de Anglais | MEDLINE | ID: mdl-38981484

RÉSUMÉ

Chlamydia trachomatis (Ct) is the most common cause for bacterial sexually transmitted infections (STIs) worldwide with a tremendous impact on public health. With the aim to unravel novel targets of the chlamydia life cycle, we screen a compound library and identify 28 agents to significantly reduce Ct growth. The known anti-infective agent pentamidine-one of the top candidates of the screen-shows anti-chlamydia activity in low concentrations by changing the metabolism of host cells impairing chlamydia growth. Furthermore, it effectively decreases the Ct burden upon local or systemic application in mice. Pentamidine also inhibits the growth of Neisseria gonorrhea (Ng), which is a common co-infection of Ct. The conducted compound screen is powerful in exploring antimicrobial compounds against Ct in a medium-throughput format. Following thorough in vitro and in vivo assessments, pentamidine emerges as a promising agent for topical prophylaxis or treatment against Ct and possibly other bacterial STIs.


Sujet(s)
Infections à Chlamydia , Chlamydia trachomatis , Modèles animaux de maladie humaine , Pentamidine , Animaux , Chlamydia trachomatis/effets des médicaments et des substances chimiques , Infections à Chlamydia/traitement médicamenteux , Infections à Chlamydia/microbiologie , Infections à Chlamydia/prévention et contrôle , Pentamidine/pharmacologie , Souris , Humains , Antibactériens/pharmacologie , Femelle , Évaluation préclinique de médicament , Gonorrhée/traitement médicamenteux , Gonorrhée/microbiologie , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Cellules HeLa
6.
J Med Virol ; 96(7): e29808, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39023086

RÉSUMÉ

To investigate the progress of disparities in human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), gonorrhea, and syphilis among children and adolescents aged 6-22 years in China during 2013-2021. A total of 614 325 cases data were extracted from the Chinese Information System for Infectious Diseases Control and Prevention during 2013-2021. Puberty health education data were drew from the Student Health Surveillance in 2021. Disparity patterns and average annual percentage changes (AAPCs) in sexually transmitted infections (STIs) incidence or new cases in China were examined using descriptive statistics and joinpoint regression. The incidence across 345 cities was stratified by gross domestic product (GDP). Between 2013 and 2021, there were 614 325 reported cases of HIV/AIDS, gonorrhea, and syphilis among children and adolescents aged 6-22, with an annual average incidence of 24.0967 per 100 000. The expansion of HIV/AIDS has halted, yet the surge in gonorrhea and syphilis remains notably pronounced. The ratio of male to female AIDS incidence increased from 2.75 (2.60, 2.90) to 7.13 (6.68, 7.62), but that of syphilis changed from 0.33 (0.32, 0.34) to 0.56 (0.55, 0.57). Students and out-of-school individuals aged 13-15 experienced a notably high increase in STI cases, surpassing other age groups, with an average annual percentage increase of 29.2% and 26.3%, respectively. Nonstudents consistently had a higher incidence rate than students, with an IRR reaching 31.80 (31.24, 32.37) in 2021. A noticeable clustering pattern of new cases emerged in the southeastern region of the Heihe-Tengchong line, extending inland from the coastal areas. Districts and counties with lower rates of puberty sexual health education tended to have higher average STI incidence rates. At the prefecture and city levels, there was a noticeable upward trend on average STI incidence rates in cities with per capita GDPs. Strategies to address those disparities include promoting equitable health education, and widespread sexual health education, particularly in areas with limited access to education and experiencing rapid economic development. The effectiveness of sexual health education intervention needs to be further evaluated in well-designed studies.


Sujet(s)
Gonorrhée , Maladies sexuellement transmissibles , Humains , Adolescent , Mâle , Femelle , Chine/épidémiologie , Incidence , Enfant , Jeune adulte , Gonorrhée/épidémiologie , Maladies sexuellement transmissibles/épidémiologie , Infections à VIH/épidémiologie , Syphilis/épidémiologie , Syndrome d'immunodéficience acquise/épidémiologie , Surveillance épidémiologique
7.
PLoS One ; 19(7): e0306695, 2024.
Article de Anglais | MEDLINE | ID: mdl-39012901

RÉSUMÉ

INTRODUCTION: Bacterial sexually transmitted infections (STIs) pose a major public health problem. The emergence of antibiotic-resistant strains of Neisseria gonorrhoeae represents a serious threat to successful treatment and epidemiological control. The first extensively drug-resistant (XDR) strains (ceftriaxone-resistant and high-level azithromycin-resistant [HLR AZY]) have been reported. AIMS: To identify molecular mechanisms implicated in azithromycin resistance in strains isolated from patients over a three-year period in a university hospital in Switzerland. MATERIAL AND METHODS: From January 2020 to December 2022, 34 isolates (one per patient) were recovered from samples analyzed at the University Hospital of Lausanne. Eight genes involved in azithromycin resistance were sequenced: mtrR repressor (mtrCDE operon repressor) and his promotor mtrR-pr, rplD gene (L4 ribosomal protein), rplV gene (L22 ribosomal protein) and the four alleles of the rrl gene (23S rRNA). RESULTS: With a cutoff value of 1 mg/L, 15 isolates were considered as being resistant to azithromycin, whereas the remaining 19 were susceptible. The C2597T mutation in 3 or 4 of the rrl allele confer a medium-level resistance to azithromycin (MIC = 16 mg/L, N = 2). The following mutations were significantly associated with MIC values ≥1 mg/L: the three mutations V125A, A147G, R157Q in the rplD gene (N = 10) and a substitution A->C in the mtrR promotor (N = 9). Specific mutations in the mtrR repressor and its promotor were observed in both susceptible and resistant isolates. CONCLUSIONS: Resistance to azithromycin was explained by the presence of mutations in many different copies of 23S RNA ribosomal genes and their regulatory genes. Other mutations, previously reported to be associated with azithromycin resistance, were documented in both susceptible and resistant isolates, suggesting they play little role, if any, in azithromycin resistance.


Sujet(s)
Antibactériens , Azithromycine , Protéines bactériennes , Résistance bactérienne aux médicaments , Mutation , Neisseria gonorrhoeae , Protéines de répression , Azithromycine/pharmacologie , Neisseria gonorrhoeae/génétique , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Humains , Protéines de répression/génétique , Résistance bactérienne aux médicaments/génétique , Protéines bactériennes/génétique , Antibactériens/pharmacologie , Tests de sensibilité microbienne , Protéines ribosomiques/génétique , Gonorrhée/microbiologie , Gonorrhée/traitement médicamenteux , Mâle , Femelle
8.
Clin Lab ; 70(7)2024 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-38965951

RÉSUMÉ

BACKGROUND: Sexually transmitted infections (STIs) increase gradually and have become a public health problem in the world. UU, CT, NG, and MG are four common STI pathogens. Our retrospective study analyzed the clinical situation and the laboratory data of patients infected with the four pathogens. The prevalence of the four pathogens, detected in urine and genital tract secretion, was studied in Hangzhou, China. METHODS: A total of 3,168 male and female patients were randomly selected from February 2023 to February 2024. Urine and genital secretions were collected, and four STI pathogens were controlled for detection. Data were collected from the hospital's electronic medical records, and SPSS 25.0 software was used to perform a statistical analysis. RESULTS: Among 3,168 patients, a total of 1,527 were detected as positive, and the positive rate was 48.20%. The age of patients ranged from 13 - 98 years, with an average age of 45.6. The total of patients consisted of 2,191 males and 977 females, which had a significant difference (p < 0.05). Specimens were mainly collected from the Department of Dermatovenerology, Urological Surgery, Obstetrics and Gynecology, and so on. The positive rate was statistically different between male and female patients (p < 0.05). Single infection performed a main role and accounted for 79.57% of all of the positive patients. In the ≤ 20 age group, the positive rate was the highest and was as high as 77.65%. In detail, single infection caused by UU dominated, especially in the 21 - 30 age group. Double infection caused by UU and CT and triple infection caused by UU, CT, and NG were the majority, both especially in the 21 - 30 age group. There were significant differences in the positive rates in the different age groups and in the four pathogens (p < 0.05). Quadruple infection was very rare and had only been detected in one patient. CONCLUSIONS: The prevalence of the four pathogens in Hangzhou was different from other regions. More male than female patients, more single than multiple infections, and more single and multiple infections occurring in young people were the features in Hangzhou. The study would provide reference for prevention, diagnosis, and treatment of STI.


Sujet(s)
Maladies sexuellement transmissibles , Humains , Mâle , Femelle , Chine/épidémiologie , Adulte , Adulte d'âge moyen , Adolescent , Prévalence , Jeune adulte , Études rétrospectives , Maladies sexuellement transmissibles/épidémiologie , Maladies sexuellement transmissibles/urine , Maladies sexuellement transmissibles/diagnostic , Maladies sexuellement transmissibles/microbiologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Gonorrhée/épidémiologie , Gonorrhée/diagnostic , Gonorrhée/urine , Gonorrhée/microbiologie , Infections à Chlamydia/épidémiologie , Infections à Chlamydia/urine , Infections à Chlamydia/diagnostic , Infections à Chlamydia/microbiologie
9.
Hum Vaccin Immunother ; 20(1): 2357924, 2024 Dec 31.
Article de Anglais | MEDLINE | ID: mdl-38976659

RÉSUMÉ

The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 countries worldwide. Real-world evidence (RWE) from the last decade confirms its effectiveness and impact, with infant immunization programs showing vaccine effectiveness of 71-95% against invasive MenB disease and cross-protection against non-B serogroups, including a 69% decrease in serogroup W cases in 4CMenB-eligible cohorts in England. RWE from different countries also demonstrates the potential for additional moderate protection against gonorrhea in adolescents. The real-world safety profile of 4CMenB is consistent with prelicensure reports. Use of the endogenous complement human serum bactericidal antibody (enc-hSBA) assay against 110 MenB strains may enable assessment of the immunological effectiveness of multicomponent MenB vaccines in clinical trial settings. Equitable access to 4CMenB vaccination is required to better protect all age groups, including older adults, and vulnerable groups through comprehensive immunization policies.


Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis(meningococcus), is rare but often devastating and can be deadly. Effective vaccines are available, including vaccines against meningococcal serogroup B disease. In 2013, the 4-component meningococcal serogroup B vaccine, 4CMenB, became the first broadly protective, protein-based vaccine against serogroup B to be licensed, with the second (bivalent vaccine, MenB-FHbp) licensed the following year. 4CMenB is now registered in more than 50 countries, in the majority, for infants and all age groups. In the US, it is approved for individuals aged 10­25 years. Evidence from immunization programs in the last decade, comparing vaccinated and unvaccinated individuals and the same population before and after vaccination, confirms the effectiveness and positive impact of 4CMenB against serogroup B disease. This also demonstrates that 4CMenB can provide protection against invasive diseases caused by other meningococcal serogroups. Furthermore, N. meningitidis is closely related to the bacterium that causes gonorrhea, N. gonorrhoeae, and emerging real-world evidence suggests that 4CMenB provides additional moderate protection against gonococcal disease. The safety of 4CMenB when given to large numbers of infants, children, adolescents, and adults is consistent with the 4CMenB safety profile reported before licensure.For the future, it would be beneficial to address differences among national guidelines for the recommended administration of 4CMenB, particularly where there is supportive epidemiological evidence but no equitable access to vaccination. New assays for assessing the potential effectiveness of meningococcal serogroup B vaccines in clinical trials are also required because serogroup B strains circulating in the population are extremely diverse across different countries.


Sujet(s)
Infections à méningocoques , Vaccins antiméningococciques , Humains , Vaccins antiméningococciques/immunologie , Vaccins antiméningococciques/administration et posologie , Infections à méningocoques/prévention et contrôle , Infections à méningocoques/immunologie , Infections à méningocoques/épidémiologie , Neisseria meningitidis sérogroupe B/immunologie , Programmes de vaccination , Gonorrhée/prévention et contrôle , Gonorrhée/immunologie , Vaccination , Nourrisson , Adolescent , Protection croisée/immunologie
10.
PLoS Pathog ; 20(7): e1012369, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38976720

RÉSUMÉ

Neisseria gonorrhoeae (the gonococcus, Gc) causes the sexually transmitted infection gonorrhea. Gc is a prominent threat to human health by causing severe lifelong sequelae, including infertility and chronic pelvic pain, which is amplified by the emergence of "superbug" strains resistant to all current antibiotics. Gc is highly adapted to colonize human mucosal surfaces, where it survives despite initiating a robust inflammatory response and influx of polymorphonuclear leukocytes (PMNs, neutrophils) that typically clear bacteria. Here, dual-species RNA-sequencing was used to define Gc and PMN transcriptional profiles alone and after infection. Core host and bacterial responses were assessed for two strains of Gc and three human donors' PMNs. Comparative analysis of Gc transcripts revealed overlap between Gc responses to PMNs, iron, and hydrogen peroxide; 98 transcripts were differentially expressed across both Gc strains in response to PMN co-culture, including iron-responsive and oxidative stress response genes. We experimentally determined that the iron-dependent TbpB is suppressed by PMN co-culture, and iron-limited Gc have a survival advantage when cultured with PMNs. Analysis of PMN transcripts modulated by Gc infection revealed differential expression of genes driving cell adhesion, migration, inflammatory responses, and inflammation resolution pathways. Production of pro-inflammatory cytokines, including IL1B and IL8, the adhesion factor ICAM1, and prostaglandin PGE2 were induced in PMNs in response to Gc. Together, this study represents a comprehensive and experimentally validated dual-species transcriptomic analysis of two isolates of Gc and primary human PMNs that gives insight into how this bacterium survives innate immune onslaught to cause disease.


Sujet(s)
Gonorrhée , Neisseria gonorrhoeae , Granulocytes neutrophiles , Transcriptome , Humains , Neisseria gonorrhoeae/immunologie , Granulocytes neutrophiles/immunologie , Granulocytes neutrophiles/métabolisme , Gonorrhée/immunologie , Gonorrhée/microbiologie
11.
Emerg Infect Dis ; 30(7): 1493-1495, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38916864

RÉSUMÉ

To determine antimicrobial susceptibility of Neisseria gonorrhoeae, we analyzed phenotypes and genomes of 72 isolates collected in Cambodia in 2023. Of those, 9/72 (12.5%) were extensively drug resistant, a 3-fold increase from 2022. Genomic analysis confirmed expansion of newly emerging resistant clones and ongoing resistance emergence across new phylogenetic backbones.


Sujet(s)
Antibactériens , Gonorrhée , Tests de sensibilité microbienne , Neisseria gonorrhoeae , Organisation mondiale de la santé , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Neisseria gonorrhoeae/génétique , Cambodge/épidémiologie , Humains , Gonorrhée/microbiologie , Gonorrhée/épidémiologie , Gonorrhée/traitement médicamenteux , Antibactériens/pharmacologie , Résistance bactérienne aux médicaments , Phylogenèse , Mâle , Femelle , Adulte
12.
Infect Immun ; 92(7): e0021124, 2024 Jul 11.
Article de Anglais | MEDLINE | ID: mdl-38864605

RÉSUMÉ

Neisseria gonorrhoeae is the etiological agent of the sexually transmitted infection gonorrhea. The pathogen is a global health challenge since no protective immunity results from infection, and far fewer treatment options are available with increasing antimicrobial resistance. With no efficacious vaccines, researchers are exploring new targets for vaccine development and innovative therapeutics. The outer membrane TonB-dependent transporters (TdTs) produced by N. gonorrhoeae are considered promising vaccine antigens as they are highly conserved and play crucial roles in overcoming nutritional immunity. One of these TdTs is part of the hemoglobin transport system comprised of HpuA and HpuB. This system allows N. gonorrhoeae to acquire iron from hemoglobin (hHb). In the current study, mutations in the hpuB gene were generated to better understand the structure-function relationships in HpuB. This study is one of the first to demonstrate that N. gonorrhoeae can bind to and utilize hemoglobin produced by animals other than humans. This study also determined that when HpuA is absent, mutations targeting extracellular loop 7 of HpuB led to defective hHb binding and utilization. However, when the lipoprotein HpuA is present, these loop 7 mutants recovered their ability to bind hHb, although the growth phenotype remained significantly impaired. Interestingly, loop 7 contains putative heme-binding motifs and a hypothetical α-helical region, both of which may be important for the use of hHb. Taken together, these results highlight the importance of loop 7 in the functionality of HpuB in binding hHb and extracting and internalizing iron.


Sujet(s)
Protéines bactériennes , Hémoglobines , Neisseria gonorrhoeae , Neisseria gonorrhoeae/métabolisme , Neisseria gonorrhoeae/génétique , Hémoglobines/métabolisme , Protéines bactériennes/métabolisme , Protéines bactériennes/génétique , Liaison aux protéines , Fer/métabolisme , Mutation , Gonorrhée/microbiologie , Protéines de la membrane externe bactérienne/métabolisme , Protéines de la membrane externe bactérienne/génétique , Animaux , Humains , Protéines de transport
13.
Curr Microbiol ; 81(8): 221, 2024 Jun 14.
Article de Anglais | MEDLINE | ID: mdl-38874629

RÉSUMÉ

Schaalia turicensis is facultative anaerobic Gram-positive bacillus that commonly inhabits the oropharynx, gastrointestinal, and genitourinary tract of healthy individuals. This organism has been co-isolated with Neisseria gonorrhoeae from 15-year-old Thai male patient with gonococcal urethritis in Bangkok, Thailand. In this study, we characterized the class 1 integron in S. turicensis isolate using whole-genome sequencing and bioinformatics analysis. Sequencing analysis confirmed the presence of an imperfect class 1 integron located on chromosome and a novel 24.5-kb-long composite transposon, named Tn7083. The transposon Tn7083 carried genes encoding chloramphenicol resistance (cmx), sulfonamide resistance (sul1), and aminoglycoside resistance [aph(6)-Id (strB), aph(3'')-Ib (strA), aph(3')-Ia].


Sujet(s)
Antibactériens , Génome bactérien , Gonorrhée , Urétrite , Humains , Mâle , Thaïlande , Urétrite/microbiologie , Gonorrhée/microbiologie , Antibactériens/pharmacologie , Adolescent , Séquençage du génome entier , Tests de sensibilité microbienne , Neisseria gonorrhoeae/génétique , Neisseria gonorrhoeae/isolement et purification , Neisseria gonorrhoeae/classification , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Éléments transposables d'ADN/génétique , Résistance bactérienne aux médicaments/génétique
14.
P R Health Sci J ; 43(2): 68-72, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38860959

RÉSUMÉ

OBJECTIVE: Monitoring the susceptibility patterns of Neisseria gonorrhoeae is essential for the continuing compliance with current treatment recommendations. Puerto Rico conducts susceptibility tests on N. gonorrhoeae; however, trends on antimicrobial resistance in the island have not been reported since the mid 80's. METHODS: We performed a secondary analysis of a national data repository on the antimicrobial susceptibility of N. gonorrhoeae isolates between 2012 and 2017; a period of time when the CDC recommended a single dose of ceftriaxone and azithromycin for the treatment of uncomplicated gonorrhea. Data on susceptibility to eight antibiotics using the standard disk diffusion method was obtained for 30.0% (84/276) of the samples collected from the Sexually Transmitted Disease clinics in Puerto Rico. We also performed patient demographic analyses linked to resistance. RESULTS: Rates of resistance to ceftriaxone and azithromycin were 0% and 4.0% (2/50), respectively. The percentage of isolates resistant to antimicrobials no longer recommended in Puerto Rico, such as tetracycline, ciprofloxacin, and penicillin, was 86.0% (43/50), 76.0% (38/50), and 38.0% (19/50), respectively. Prevalence of resistant N. gonorrhoeae was higher among men who have sex with men, MSM (79%, 37/47). DISCUSSION: Lack of resistance to ceftriaxone and slow emergence of azithromycin resistance was identified from 2012-2017. It is imperative to continue the surveillance for emerging patterns of resistance, especially for ceftriaxone, as it is part of the current treatment guidelines. Therefore, protocols for culture based surveillance, including sample transport and processing, should be strengthened to ensure quality assured epidemiology of gonococcal resistance in Puerto Rico.


Sujet(s)
Antibactériens , Résistance bactérienne aux médicaments , Gonorrhée , Tests de sensibilité microbienne , Neisseria gonorrhoeae , Porto Rico , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Neisseria gonorrhoeae/isolement et purification , Humains , Mâle , Gonorrhée/traitement médicamenteux , Gonorrhée/microbiologie , Gonorrhée/épidémiologie , Femelle , Antibactériens/pharmacologie , Antibactériens/administration et posologie , Adulte , Jeune adulte , Azithromycine/pharmacologie , Azithromycine/administration et posologie , Ceftriaxone/pharmacologie , Adolescent , Adulte d'âge moyen
15.
Int J Mol Sci ; 25(11)2024 May 26.
Article de Anglais | MEDLINE | ID: mdl-38891969

RÉSUMÉ

The increasing problem of antimicrobial resistance in N. gonorrhoeae necessitates the development of molecular typing schemes that are suitable for rapid and mass screening. The objective of this study was to design and validate a mini-MLST scheme for N. gonorrhoeae based on global pathogen population data. Using sequences of seven housekeeping genes of 21,402 isolates with known MLSTs from the PubMLST database, we identified eighteen informative polymorphisms and obtained mini-MLST nucleotide profiles to predict MLSTs of isolates. We proposed a new MLST grouping system for N. gonorrhoeae based on mini-MLST profiles. Phylogenetic analysis revealed that MLST genogroups are a stable characteristic of the N. gonorrhoeae global population. The proposed grouping system has been shown to bring together isolates with similar antimicrobial susceptibility, as demonstrated by the characteristics of major genogroups. Established MLST prediction algorithms based on nucleotide profiles are now publicly available. The mini-MLST scheme was evaluated using a MLST detection/prediction method based on the original hydrogel DNA microarray. The results confirmed a high predictive ability up to the MLST genogroup. The proposed holistic approach to gonococcal population analysis can be used for the continuous surveillance of known and emerging resistant N. gonorrhoeae isolates.


Sujet(s)
Gonorrhée , Typage par séquençage multilocus , Neisseria gonorrhoeae , Phylogenèse , Neisseria gonorrhoeae/génétique , Neisseria gonorrhoeae/classification , Typage par séquençage multilocus/méthodes , Gonorrhée/microbiologie , Gonorrhée/diagnostic , Humains , Techniques de typage bactérien/méthodes
16.
Expert Opin Ther Pat ; 34(6): 511-524, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38856987

RÉSUMÉ

INTRODUCTION: Neisseria gonorrhoeae is a common sexually transmitted disease connected with extensive drug resistance to many antibiotics. Presently, only expanded spectrum cephalosporins (ceftriaxone and cefixime) and azithromycin remain useful for its management. AREAS COVERED: New chemotypes for the classical antibiotic drug target gyrase/topoisomerase IV afforded inhibitors with potent binding to these enzymes, with an inhibition mechanism distinct from that of fluoroquinolones, and thus less prone to mutations. The α-carbonic anhydrase from the genome of this bacterium (NgCAα) was also validated as an antibacterial target. EXPERT OPINION: By exploiting different subunits from the gyrase/topoisomerase IV as well as new chemotypes, two new antibiotics reached Phase II/III clinical trials, zoliflodacin and gepotidacin. They possess a novel inhibition mechanism, binding in distinct parts of the enzyme compared to the fluoroquinolones. Other chemotypes with inhibitory activity in these enzymes were also reported. NgCAα inhibitors belonging to a variety of classes were obtained, with several sulfonamides showing MIC values in the range of 0.25-4 µg/mL and significant activity in animal models of this infection. Acetazolamide and similar CA inhibitors might thus be repurposed as antiinfectives. The scientific/patent literature has been searched for on PubMed, ScienceDirect, Espacenet, and PatentGuru, from 2016 to 2024.


Sujet(s)
Antibactériens , Repositionnement des médicaments , Résistance bactérienne aux médicaments , Gonorrhée , Neisseria gonorrhoeae , Brevets comme sujet , Neisseria gonorrhoeae/effets des médicaments et des substances chimiques , Neisseria gonorrhoeae/enzymologie , Antibactériens/pharmacologie , Humains , Animaux , Gonorrhée/traitement médicamenteux , Gonorrhée/microbiologie , Inhibiteurs de la topoisomérase-II/pharmacologie , Oxazolidinones/pharmacologie , Tests de sensibilité microbienne , DNA topoisomerase IV/antagonistes et inhibiteurs , DNA topoisomerase IV/métabolisme , DNA gyrase/métabolisme , Morpholines , Isoxazoles , Spiranes , Composés hétérocycliques 3 noyaux , Barbituriques , Acénaphtène
17.
BMJ Open ; 14(6): e073565, 2024 Jun 16.
Article de Anglais | MEDLINE | ID: mdl-38885995

RÉSUMÉ

INTRODUCTION: In 2016, WHO estimated there were roughly 374 million new infections among adults of the following four curable sexually transmitted infections (STIs): chlamydia (caused by Chlamydia trachomatis (CT)), gonorrhoea (Neisseria gonorrhoeae (NG)), syphilis (Treponema pallidum) and trichomoniasis (Trichomonas vaginalis (TV)). Accurate point-of-care tests (POCTs) for screening of genital and extragenital CT, NG and TV infections are of great value and have been developed during recent decade. Several tests are commercially available and have shown encouraging performance compared with 'gold-standard' reference tests in laboratory-based studies. However, there is limited data on their clinical performance, including at the POC. Key populations, such as men who have sex with men (MSM), are at higher risk of these STIs at genital and extragenital sites and these STIs are often asymptomatic, especially in extragenital sites and in women. We will conduct a clinical-based evaluation to assess the performance characteristics and acceptability to end-users of molecular-based diagnostic technology for POC/near patient use of the Xpert CT/NG (Cepheid, Sunnyvale, California, USA) test for screening of genital, anorectal and pharyngeal CT and NG infections in MSM and the Xpert CT/NG and Xpert TV (Cepheid, Sunnyvale, California, USA) for screening of genital CT, NG and TV among women at risk for these STIs compared with gold-standard reference nucleic acid amplification tests. This master protocol outlines the overall research approach that will be used in seven countries. METHOD AND ANALYSES: Consecutive MSM and women at risk presenting at the clinical sites in high, and low- and middle-income countries will be enrolled. The POCTs to be evaluated are Xpert CT/NG and Xpert TV. All procedures will be carried out by trained healthcare staff and tests performed in strict accordance with the manufacturer's instructions. The sensitivity, specificity, positive and negative predictive values for each POCT will be calculated. The study is ongoing with recruitment expected to be completed in all countries by mid-2022 to late-2022. ETHICS AND DISSEMINATION: Prior to enrolment, this core protocol was independently peer-reviewed and approved by the research project review panel (RP2) of the WHO Department of Sexual and Reproductive Health and Research and by the WHO Ethics Review Committee (ERC). The core protocol has been slightly adapted accordingly to individual countries and adaptations approved by both RP2 and ERC, as well as all relevant institutional review boards at each participating site. Results will be disseminated through peer-reviewed journals and presented at relevant national/international conferences.


Sujet(s)
Infections à Chlamydia , Gonorrhée , Homosexualité masculine , Analyse sur le lieu d'intervention , Humains , Mâle , Femelle , Infections à Chlamydia/diagnostic , Gonorrhée/diagnostic , Études prospectives , Dépistage de masse/méthodes , Trichomonas vaginalis/isolement et purification , Maladies sexuellement transmissibles/diagnostic , Vaginite à Trichomonas/diagnostic , Vaginite à Trichomonas/épidémiologie , Études multicentriques comme sujet , Sensibilité et spécificité , Adulte , Systèmes automatisés lit malade
18.
Afr J Reprod Health ; 28(4): 90-110, 2024 Apr 30.
Article de Anglais | MEDLINE | ID: mdl-38904761

RÉSUMÉ

Despite significant research on the prevalence of STIs in South African men who have sex with men (MSM), recent data on the prevalence and risk factors for curable STI infections among this key populations are limited. This study determined the prevalence of and risk factors associated with Neisseria gonorrhoeae and Chlamydia trachomatis infections among MSM. The sample consisted of 200 MSM resident in Durban. Data were collected using a self-administered questionnaire, and urine samples were collected and tested for N. gonorrhoeae and C. trachomatis. The prevalence of N. gonorrhoeae and C. trachomatis were 3.0% and 6.0%, respectively. Younger age was significantly associated with testing positive for C. trachomatis (p=0.037). Being between the ages of 30-39 years old reduced the risk of acquiring C. trachomatis infection (OR: 0.10, 95% CI: 0.0120-0.7564, p=0.026). In addition, being circumcised reduced the risk of contracting C. trachomatis (adjusted OR: 0.01, 95% CI: 0.0005-0.3516, p=0.01). However, having between 2-4 sex partners increased the risk of testing positive for C. trachomatis (adjusted OR: 107.45, 95% CI: 1.3467-8573.3130, p=0.036). The following factors were significantly associated (p<0.05) with testing positive for N. gonorrhoeae infection: cohabiting with sex partner, engaging in group sex, and drug use. Fear and stigma were the main barriers to accessing health care in the studied population. This study provided evidence of high rates of C. trachomatis infection among MSM resident in Durban. Based on the results, South African MSM, especially the young MSM population, should be given priority when delivering intervention programs to prevent STIs.


Malgré des recherches importantes sur la prévalence des IST chez les hommes sud-africains ayant des rapports sexuels avec des hommes (HSH), les données récentes sur la prévalence et les facteurs de risque d'infections IST curables parmi ces populations clés sont limitées. Cette étude a déterminé la prévalence et les facteurs de risque associés aux infections à Neisseria gonorrhoeae et à Chlamydia trachomatis chez les HARSAH. L'échantillon était composé de 200 HSH résidant à Durban. Les données ont été collectées à l'aide d'un questionnaire auto-administré et des échantillons d'urine ont été collectés et testés pour N. gonorrhoeae et C. trachomatis. La prévalence de N. gonorrhoeae et de C. trachomatis était respectivement de 3,0 % et 6,0 %. Un âge plus jeune était significativement associé à un test positif pour C. trachomatis (p = 0,037). Le fait d'être âgé de 30 à 39 ans réduisait le risque de contracter une infection à C. trachomatis (OR : 0,10, IC à 95 % : 0,0120-0,7564, p = 0,026). De plus, être circoncis réduisait le risque de contracter C. trachomatis (OR ajusté : 0,01, IC à 95 % : 0,0005-0,3516, p=0,01). Cependant, avoir entre 2 et 4 partenaires sexuels augmentait le risque d'être testé positif pour C. trachomatis (OR ajusté : 107,45, IC à 95 % : 1,3467-8573,3130, p=0,036). Les facteurs suivants étaient significativement associés (p < 0,05) au test positif pour l'infection à N. gonorrhoeae : cohabitation avec un partenaire sexuel, participation à des relations sexuelles en groupe et consommation de drogues. La peur et la stigmatisation étaient les principaux obstacles à l'accès aux soins de santé dans la population étudiée. Cette étude a mis en évidence des taux élevés d'infection à C. trachomatis parmi les HSH résidant à Durban. Sur la base des résultats, les HSH sud-africains, en particulier la jeune population HSH, devraient être prioritaires lors de la mise en œuvre de programmes d'intervention visant à prévenir les IST.


Sujet(s)
Infections à Chlamydia , Chlamydia trachomatis , Gonorrhée , Homosexualité masculine , Neisseria gonorrhoeae , Humains , Mâle , Gonorrhée/épidémiologie , Infections à Chlamydia/épidémiologie , République d'Afrique du Sud/épidémiologie , Adulte , Prévalence , Facteurs de risque , Homosexualité masculine/statistiques et données numériques , Neisseria gonorrhoeae/isolement et purification , Chlamydia trachomatis/isolement et purification , Jeune adulte , Partenaire sexuel , Comportement sexuel , Études transversales , Enquêtes et questionnaires , Adolescent
19.
Sante Publique ; 36(3): 137-146, 2024.
Article de Français | MEDLINE | ID: mdl-38906808

RÉSUMÉ

OBJECTIVE OF THE STUDY: To estimate the prevalence of four STIs in women of reproductive age in the Kara region. METHODS: A cross-sectional study was conducted in March 2022. Data were collected using a standardized questionnaire. Screening for HIV and syphilis was performed using the SD-BIOLINE HIV/Syphilis Duo® rapid tests. The GeneXpert PCR technique was used to test for Chlamydia trachomatis and Neisseria gonorrhoeae. The prevalences of STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, and HIV) were reported with 95% confidence intervals. RESULTS: A total of 300 women with a median age of 32 years (interquartile range 24–39) were included. Of these, 25.7% had consulted a gynecologist in the last twelve months. The prevalence of Chlamydia trachomatis was 4.3% (95% CI [2.4–7.5]); Neisseria gonorrhoeae 3.3% [95% CI: 1.7–6.2], Treponema pallidum 0.3% [95% CI: 0.02–2.1] and HIV 3.7% [95% CI: 1.9–6.7]. Three cases of co-infection with Neisseria gonorrhoeae and Chlamydia trachomatis were reported; no cases of co-infection with HIV and bacterial STIs were reported. CONCLUSION: This study confirms the women’s limited access to gynecological consultations, the low circulation of syphilis, and the presence of Neisseria gonorrhoeae and Chlamydia trachomatis in women of reproductive age in the Kara region. An STI surveillance system is needed to improve STI management among this population.


Sujet(s)
Infections à Chlamydia , Gonorrhée , Humains , Femelle , Adulte , Études transversales , Prévalence , Jeune adulte , Infections à Chlamydia/épidémiologie , Gonorrhée/épidémiologie , Syphilis/épidémiologie , Infections à VIH/épidémiologie , Maladies sexuellement transmissibles/épidémiologie , Chlamydia trachomatis/isolement et purification , Adulte d'âge moyen
20.
J Infect Public Health ; 17(7): 102447, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38824739

RÉSUMÉ

BACKGROUND: Current clinical care for common bacterial STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG)) involves empiric antimicrobial therapy when clients are symptomatic, or if asymptomatic, waiting for laboratory testing and recall if indicated. Near-to-patient testing (NPT) can improve pathogen-specific prescribing and reduce unnecessary or inappropriate antibiotic use in treating sexually transmitted infections (STI) by providing same-day delivery of results and treatment. METHODS: We compared the economic cost of NPT to current clinic practice for managing clients with suspected proctitis, non-gonococcal urethritis (NGU), or as an STI contact, from a health provider's perspective. With a microsimulation of 1000 clients, we calculated the cost per client tested and per STI- and pathogen- detected for each testing strategy. Sensitivity analyses were conducted to assess the robustness of the main outcomes. Costs are reported as Australian dollars (2023). RESULTS: In the standard care arm, cost per client tested for proctitis, NGU in men who have sex with men (MSM) and heterosexual men were the highest at $247.96 (95% Prediction Interval (PI): 246.77-249.15), $204.23 (95% PI: 202.70-205.75) and $195.01 (95% PI: 193.81-196.21) respectively. Comparatively, in the NPT arm, it costs $162.36 (95% PI: 161.43-163.28), $158.39 (95% PI: 157.62-159.15) and $149.17 (95% PI: 148.62-149.73), respectively. Using NPT resulted in cost savings of 34.52%, 22.45% and 23.51%, respectively. Among all the testing strategies, substantial difference in cost per client tested between the standard care arm and the NPT arm was observed for contacts of CT or NG, varying from 27.37% to 35.28%. CONCLUSION: We found that NPT is cost-saving compared with standard clinical care for individuals with STI symptoms and sexual contacts of CT, NG, and MG.


Sujet(s)
Maladies sexuellement transmissibles , Humains , Mâle , Femelle , Maladies sexuellement transmissibles/diagnostic , Maladies sexuellement transmissibles/économie , Maladies sexuellement transmissibles/traitement médicamenteux , Gonorrhée/diagnostic , Gonorrhée/économie , Gonorrhée/traitement médicamenteux , Australie , Adulte , Analyse coût-bénéfice , Infections à Chlamydia/diagnostic , Infections à Chlamydia/économie , Infections à Chlamydia/traitement médicamenteux , Chlamydia trachomatis , Neisseria gonorrhoeae/isolement et purification , Mycoplasma genitalium , Dépistage de masse/économie , Dépistage de masse/méthodes , Infections à Mycoplasma/diagnostic , Infections à Mycoplasma/traitement médicamenteux , Infections à Mycoplasma/économie , Urétrite/diagnostic , Urétrite/économie , Urétrite/traitement médicamenteux , Urétrite/microbiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...